Vitrolife AB (STO:VITR), an international medical device company, announced on Monday the decision by Barbro Fridén to step down as a member of the board of directors of the company, reportedly due to other future opportunities.
Fridén has been a member of the board of Vitrolife since 2010.
Vitrolife develops, produces and markets medical devices for assisted reproduction.
Headquartered in Gothenburg, Sweden, with offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, the UK and US, Vitrolife employs about 400 people and its products are sold in approximately 110 markets.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA